Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Innocoll starts Phase II trial for diabetic foot ulcer treatment
Innocoll plans to study CollaRx gentamicin topical for the treatment of diabetic foot infections of varying severity in a series of Phase II trials and has appointed the
Innocoll plans to study CollaRx gentamicin topical for the treatment of diabetic foot infections of varying severity in a series of Phase II trials and has appointed the
The ANDES (AGI-1067 as a novel antidiabetic agent evaluation study) trial has enrolled 999 patients with type II diabetes at approximately 150 clinical sites in the US, South
A-001 is currently being evaluated for acute chest syndrome in a Phase II clinical trial in the US called IMPACTS (investigation of the modulation of phospholipase in acute
The results showed that a single dose of ABthrax, administered without concomitant antibiotics, improved survival rates by up to 64% when administered after animals were symptomatic for anthrax
The new drug application (NDA) for Aquavan was submitted to the FDA on September 27, 2007. The acceptance for review of the NDA represents the FDA’s determination that
The trial will evaluate MP470 in combination with several standard of care chemotherapy regimens, including carboplatin/paclitaxel, carboplatin/etoposide, docetaxel, topotecan and erlotinib. The trial is expected to enroll up
Pending the receipt of all necessary regulatory approvals, Angiotech anticipates launching the commercial 5-fluorouracil-coated (5-FU) central venous catheter (CVC) product line in 2008. William Hunter, president and CEO
The existing principal shareholders, Rolf and William Schmidt, also converted existing loans totaling approximately $16 million into convertible preferred stock. The financing will be used to fund a
Ambrx said that the collaboration will apply its protein optimization technology, ReCODE, with Lilly’s expertise in biologics discovery, development and commercialization to pursue first-in-class or best-in-class drug candidates,
The transaction is expected to be completed by the end of January 2008, subject to customary regulatory approvals, at which time Bristol-Myers Squibb Medical Imaging (BMS MI) will